Pharmacotherapy for cannabis dependence: how close are we?

Area of Science:

• Addiction Medicine
• Psychopharmacology
• Cannabinoid Science

Background:

• Cannabis is the world's most frequently used illicit substance.
• Increasing rates of cannabis use disorder (CUD) admissions highlight the need for effective treatments.
• Developing pharmacotherapy for CUD is a research and clinical priority.

Purpose of the Study:

• To review current research on medications for treating cannabis use disorders.
• To identify potential therapeutic agents that may reduce withdrawal, craving, or relapse.
• To assess the current evidence base and identify gaps in clinical research.

Main Methods:

• Literature review of medications investigated for CUD treatment.
• Categorization of medications based on their proposed mechanisms of action (e.g., treating other substance use disorders, alleviating withdrawal, affecting cannabinoid receptors).
• Analysis of findings from controlled laboratory and small open-label clinical studies.

Main Results:

• Several medications, including buspirone, dronabinol, fluoxetine, lithium, and lofexidine, show potential therapeutic benefits in preliminary studies.
• These agents have demonstrated effects such as reduced withdrawal symptoms and attenuation of subjective effects.
• Evidence primarily comes from laboratory and small open-label studies, not large-scale controlled clinical trials.

Conclusions:

• Promising candidate medications for CUD pharmacotherapy have been identified.
• Controlled clinical trials are critically needed to validate the efficacy of these medications.
• Further research is required to confirm findings and support the clinical application of these drugs for treating cannabis use disorders.